Register to get unlimited access to all of Citywire’s fund manager database. Registration is free and only takes a minute.

FDA 14 - O (C/D)

Ranked 133 out of 866 in - US over 12 months
All calculations are in USD unless stated

Objective

The management objective of the fund is to outperform the MSCI USA. The fund's exposure to shares can vary between -100% and 200% of its net assets. The fund's investment universe is centered on large and mid caps equities of North America.

Showing fund performance globally. You can view performance in individual jurisdictions.

Performance

US over : 30/09/2016 - 30/09/2017
  • Rank 133/866 Total Return
  • Rank 715/866 Standard Deviation
  • Rank 802/866 Max Drawdown
Fund Name Currency Loss
800 BGF US Basic Value A2 USD

Currency exposure is hedged

Currency exposure is hedged

USD

-4.5%

801 Investors U.S. Opportunities Class Series A USD

-4.5%

802 FDA 14 - O (C/D) USD

-4.5%

803 RBC U.S. Equity Currency Neutral Sr A USD

-4.6%

804 Wells Fargo (LUX) WW US Select Eq A USD USD

-4.6%

Total Return

Quarterly Performance

to 29/09/2017 Annual Q1 Q2 Q3 Q4
2017 6.2% 8.8% 7.6%
2016 2.7% 1.9% -1.3% 5.3% -3.0%
2015 -9.4% -8.6% 2.8% -6.7% 3.4%
2014 -7.7% 1.7% 4.3% -6.8% -6.6%
2013 25.2% 6.1% 2.1% 6.5% 8.5%
2012 11.7% 13.7% -8.4% 7.7% -0.4%
2011 -0.5% -20.8% 9.0%

Month by Month Performance

Returns Vs Risk

Registered For Sale In

  1. France

Fund Info

  • Launch date03/03/2011
  • Share Class size13Mn
  • Base currencyEUR
  • ISIN FR0010998385

Purchase Info

  • Min. initial investment10,000
  • Min. regular additional investment0

Charges

Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in USD).